- $2.10bn
- $1.94bn
- $276.26m
Vericel Corp reports results for the quarter ended in March - Earnings Summary
Brief: Vericel Reports Q1 2023 Financial Results And Raises FY 2023 Financial Guidance
Brief: Vericel sees Outlook FY revenue USD 184-192 million
Vericel Corp reports results for the quarter ended in December - Earnings Summary
Brief: Vericel Expects FY Revenue $180-$188 Million
Vericel Corp expected to post earnings of 4cents a share - Earnings Preview
Vericel jumps as preliminary FY 2022 sales in line with expectations
Brief: Vericel Corp Sees FY Revenue Of About $164.0 Mln To $165.0 Mln
Vericel jumps as FDA approves treatment for burns
Brief: Mediwound Announces FDA Approval Of Nexobrid® For The Treatment Of Severe Thermal Burns In Adults
Brief: Vericel Announces FDA Approval Of Nexobrid For The Treatment Of Severe Thermal Burns In Adults
Brief: Vericel Reports Third Quarter Results
Vericel Corp reports results for the quarter ended in September - Earnings Summary
Vericel Corp expected to post a loss of 10 cents a share - Earnings Preview
Brief: Mediwound Announces U.S. FDA Acceptance Of Biologics License Application For Nexobrid For Treatment Of Severe Thermal Burns
Brief: Vericel Publishes Positive Results From Retrospective Study By The BRCA Of Patients With Large Posterior Trunk Burns Treated With Epicel
U.S. STOCKS ON THE MOVE-Netflix, Kraft Heinz, travel stocks
U.S. STOCKS ON THE MOVE-Cruise stocks, Advent Technologies, Expensify Inc
U.S. STOCKS ON THE MOVE-China ADRs, energy companies, Boeing